Peptides8 min read
BPC-157 arginate versus acetate: what the formulation evidence shows
What salt names, patent stability tests and animal pharmacokinetics can tell you about BPC-157 capsules—and what still needs a human comparison.
Read articleBlog
Research, explained. Explore peptides, supplements and hormone health with clear, practical breakdowns of what the studies actually tell us.
Peptides articles
All articlesMetabolism, recovery and emerging research
Peptides9 min read
Selank and anxiety: what a change in a symptom score can tell you
Small Selank reports describe anxiety improvement. Learn how symptom scales, daily function, comparator treatments and follow-up shape what those findings mean.
Read article
Peptides8 min read
Does Selank avoid sedation? What the studies actually measured
Sleepiness, reaction time and cognitive performance are different outcomes. Explore what Selank tolerability reports do and do not establish.
Read article
Peptides9 min read
Thymosin beta-4 and cancer: what conflicting experiments mean
Thymosin beta-4 has shown different effects across cancer models. Learn what overexpression, cell-exposure and mouse studies can say about human safety.
Read article
Peptides9 min read
What functional brain imaging adds to kisspeptin research
Kisspeptin studies use brain scans to explore sexual responses. Learn what BOLD imaging adds, how the trials worked and why lasting benefit is a separate question.
Read article
Peptides9 min read
Why an eloralintide dose-ranging trial isn't a dosing guide
Research schedules help identify a treatment worth testing further. They don't establish a personal starting dose, conversion or combination protocol.
Read article
Peptides9 min read
CJC-1295 half-life: what lasts for days, and why does it matter?
Separate CJC-1295 exposure from GH secretion and IGF-1 response, including the human pulse study and the limits of timing-based treatment claims.
Read article
Peptides9 min read
ARA-290 and metabolic outcomes: what the diabetes study actually found
The diabetes trial planned HbA1c as a primary outcome. Its small changes, lipid findings and follow-up still leave important treatment questions open.
Read article
Peptides9 min read
Why the older DSIP sleep trials reached different conclusions
A closer look at the people, placebo comparisons and sleep measurements behind the conflicting older DSIP reports.
Read article
Peptides8 min read
DSIP and deep sleep: what an EEG can actually establish
What scalp EEG, deep-sleep staging and a small anaesthesia experiment can tell us about DSIP and restorative sleep.
Read article
Peptides8 min read
Why MOTS-c studies disagree about blood levels
Different obesity and aging studies report different MOTS-c patterns. Population, tissue, timing, units and assay methods explain why comparisons need care.
Read article
Peptides9 min read
KPV in 2026: what human research still needs to answer
What KPV's intestinal and skin research shows, how the K(D)PT trial differs, and which patient questions remain after the 2026 discussion.
Read article241–252 of 320 articles